For clinicians

Mixed and undifferentiated connective tissue disease

MCTD, mixed connective tissue disease, UCTD, undifferentiated connective tissue disease

Looking for the plain-language version? See the patient version of this page.

Bottom lineBottom line: manage according to the dominant clinical features and antibody profile. Key reproductive considerations are anti-Ro/SSA co-positivity (neonatal lupus and CHB surveillance) and, given scleroderma-spectrum overlap, screening for pulmonary arterial hypertension. UCTD may evolve, so reassess. Continue hydroxychloroquine; individualise the rest.

By domain

A plan tailored to your features ●●○○low evidenceconditional

Management is feature-led: base monitoring and therapy on the dominant manifestations and serologies rather than the label alone.[1]

Anti-Ro/SSA antibodies ●●●○moderate evidenceconditional

Screen for anti-Ro/SSA; if positive, follow the neonatal-lupus and congenital heart block pathway (see the anti-Ro atom).[1, 3]

Lung artery pressure ●●○○low evidenceconditional

Given scleroderma-spectrum overlap, pulmonary arterial hypertension is a recognised concern; pre-conception echocardiographic screening is reasonable and significant PAH is a high-risk situation. This is general clinical reasoning by analogy to systemic sclerosis, not a claim from an MCTD-specific pregnancy source; a dedicated reference should be attached.

Medicines ●●●○moderate evidenceconditional

Continue hydroxychloroquine; select additional therapy per dominant features using compatible agents; avoid mycophenolate, methotrexate, cyclophosphamide.[1, 2]

Key points

PointEvidence
Feature-led, serology-informed management is the organising principle.[1]●●○○low evidenceconditional

References

  1. Sammaritano LR, et al. 2020 ACR Guideline for the Management of Reproductive Health in RMD. Arthritis Rheumatol. 2020;72(3):529-556. https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.41191
  2. Ruegg L, et al. EULAR recommendations for antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update. Ann Rheum Dis. 2025;84(6):910-926. https://ard.eular.org/article/S0003-4967(25)00818-0/fulltext
  3. Izmirly P, et al. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block (PATCH). J Am Coll Cardiol. 2020;76(3):292-302. https://www.jacc.org/doi/10.1016/j.jacc.2020.05.045